Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tariq E Farrah

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Kidney International|February 27, 2021
Antineutrophil cytoplasm antibody positivity, kidney impairment, and cholesterol embolizationTariq E Farrah, Neeraj Dhaun
Nature Reviews. Cardiology|May 16, 2019
Retinal fingerprints for precision profiling of cardiovascular riskTariq E Farrah, David J Webb, Neeraj Dhaun
British Journal of Pharmacology|November 14, 2019
Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular diseaseNikolaos Tzoumas, Tariq E Farrah, Neeraj Dhaun, et al.
Rheumatology Advances in Practice|August 13, 2025
Weight gain following a diagnosis of anti-neutrophil cytoplasmic antibody-associated vasculitisTania Salehi, Thomas French, Tariq E Farrah, et al.
Kidney International|May 31, 2020
The eye, the kidney, and cardiovascular disease: old concepts, better tools, and new horizonsTariq E Farrah, Baljean Dhillon, Pearse A Keane, et al.
Kidney International Reports|March 23, 2019
Cyclophosphamide-Induced Lung InjuryDan Pugh, Tariq E Farrah, Peter J Gallacher, et al.
BMJ (Clinical Research Ed.)|April 16, 2020
ANCA associated vasculitisRobert W Hunter, Nicola Welsh, Tariq E Farrah, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 14, 2019
Advances in Therapies and Imaging for Systemic VasculitisTariq E Farrah, Neil Basu, Marc Dweck, et al.
Kidney International|January 3, 2018
Endothelin antagonism reduces circulating galectin-3 in patients with proteinuric chronic kidney diseaseTariq E Farrah, Atul Anand, Eve Miller-Hodges, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 4, 2016
Symptomatic fracture risk in the renal replacement therapy populationVishal Dey, Tariq E Farrah, Jamie P Traynor, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Kidney International|February 27, 2021
Antineutrophil cytoplasm antibody positivity, kidney impairment, and cholesterol embolizationTariq E Farrah, Neeraj Dhaun
Nature Reviews. Cardiology|May 16, 2019
Retinal fingerprints for precision profiling of cardiovascular riskTariq E Farrah, David J Webb, Neeraj Dhaun
British Journal of Pharmacology|November 14, 2019
Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular diseaseNikolaos Tzoumas, Tariq E Farrah, Neeraj Dhaun, et al.
Rheumatology Advances in Practice|August 13, 2025
Weight gain following a diagnosis of anti-neutrophil cytoplasmic antibody-associated vasculitisTania Salehi, Thomas French, Tariq E Farrah, et al.
Kidney International|May 31, 2020
The eye, the kidney, and cardiovascular disease: old concepts, better tools, and new horizonsTariq E Farrah, Baljean Dhillon, Pearse A Keane, et al.
Kidney International Reports|March 23, 2019
Cyclophosphamide-Induced Lung InjuryDan Pugh, Tariq E Farrah, Peter J Gallacher, et al.
BMJ (Clinical Research Ed.)|April 16, 2020
ANCA associated vasculitisRobert W Hunter, Nicola Welsh, Tariq E Farrah, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 14, 2019
Advances in Therapies and Imaging for Systemic VasculitisTariq E Farrah, Neil Basu, Marc Dweck, et al.
Kidney International|January 3, 2018
Endothelin antagonism reduces circulating galectin-3 in patients with proteinuric chronic kidney diseaseTariq E Farrah, Atul Anand, Eve Miller-Hodges, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 4, 2016
Symptomatic fracture risk in the renal replacement therapy populationVishal Dey, Tariq E Farrah, Jamie P Traynor, et al.
Pageof 3